CN1225258C - 一种治疗胰腺癌的中药复方制剂 - Google Patents
一种治疗胰腺癌的中药复方制剂 Download PDFInfo
- Publication number
- CN1225258C CN1225258C CN 02136330 CN02136330A CN1225258C CN 1225258 C CN1225258 C CN 1225258C CN 02136330 CN02136330 CN 02136330 CN 02136330 A CN02136330 A CN 02136330A CN 1225258 C CN1225258 C CN 1225258C
- Authority
- CN
- China
- Prior art keywords
- pancreatic cancer
- pancreas
- present
- cancer
- compound preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 25
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title abstract description 24
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract description 11
- 201000002528 pancreatic cancer Diseases 0.000 title abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 210000000582 semen Anatomy 0.000 claims description 11
- 241000222336 Ganoderma Species 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 15
- 210000000496 pancreas Anatomy 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 239000008187 granular material Substances 0.000 abstract description 5
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract description 2
- 229920002752 Konjac Polymers 0.000 abstract description 2
- 240000001659 Oldenlandia diffusa Species 0.000 abstract description 2
- 241000915604 Scutellaria barbata Species 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000006188 syrup Substances 0.000 abstract description 2
- 235000020357 syrup Nutrition 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 235000010485 konjac Nutrition 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 230000004083 survival effect Effects 0.000 description 14
- 238000002512 chemotherapy Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 240000002943 Elettaria cardamomum Species 0.000 description 8
- 235000005300 cardamomo Nutrition 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 102000011759 adducin Human genes 0.000 description 4
- 108010076723 adducin Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000012820 exploratory laparotomy Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241001127714 Amomum Species 0.000 description 1
- 241001312219 Amorphophallus konjac Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010062693 Gallbladder enlargement Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
贮存时间(室温) | 性状 | 鉴别 | 重量差异 | 浓度时限 | |
蛇六谷的TLC | 蛇舌草的TLC | ||||
0(00.1.83℃)1(00.2.81℃)2(00.3.811℃)3(00.4.818℃)4(00.5.829℃)5(00.6.831℃)6(00.7.835℃)标准规定 | 淡黄色颗粒状淡黄色颗粒状淡黄色颗粒状淡黄色颗粒状淡黄色颗粒状淡黄色颗粒状淡黄色颗粒状(表面发粘)淡黄色颗粒状 | 阳性阳性阳性阳性阳性阳性阳性阳性 | 阳性阳性阳性阳性阳性阳性阳性阳性 | 符合规定符合规定符合规定符合规定符合规定符合规定符合规定≤±7.5% | 符合规定符合规定符合规定符合规定符合规定符合规定符合规定<60分钟 |
组别 | 实验1 | 实验2 | 实验3 | |||
瘤重g | 抑瘤率% | 瘤重g | 抑瘤率% | 瘤重g | 抑瘤率% | |
生理盐水组高剂量组中剂量组低剂量组 | 3.19±1.131.89±0.631.99±0.542.21±0.31 | 40.75*37.61*30.72* | 3.17±0.931.85±0.531.97±0.412.19±0.51 | 41.64*37.85*30.91* | 3.02±0.151.80±0.852.01±0.542.21±0.64 | 40.39*33.44*30.13* |
组别 | 实验1 | 实验2 | ||||
体重变化(g) | 瘤重(g) | 抑瘤率(%) | 体重变化(g) | 瘤重(g) | 抑瘤率(%) | |
生理盐水组CTX组高剂量组中剂量组低剂量组 | +4.91_1.56+4.15+4.65+4.81 | 2.89±1.11.03±0.151.64±0.471.81±0.592.01±0.41 | 64.35*43.25*37.37*30.44* | +4.17_2.10+3.15+3.67+4.01 | 2.98±0.961.12±0.201.71±0.541.87±0.641.95±0.78 | 62.42*42.62*37.25*34.56* |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02136330 CN1225258C (zh) | 2002-08-01 | 2002-08-01 | 一种治疗胰腺癌的中药复方制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02136330 CN1225258C (zh) | 2002-08-01 | 2002-08-01 | 一种治疗胰腺癌的中药复方制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1391949A CN1391949A (zh) | 2003-01-22 |
CN1225258C true CN1225258C (zh) | 2005-11-02 |
Family
ID=4748602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02136330 Expired - Fee Related CN1225258C (zh) | 2002-08-01 | 2002-08-01 | 一种治疗胰腺癌的中药复方制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1225258C (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103800731A (zh) * | 2012-11-05 | 2014-05-21 | 复旦大学附属肿瘤医院 | 一种调控胰腺癌干细胞的中药复方制剂 |
CN103071104B (zh) * | 2013-01-21 | 2015-01-07 | 戴玲玲 | 一种治疗中晚期胰腺癌的中药复方制剂 |
CN104524420B (zh) * | 2015-01-31 | 2018-07-06 | 青岛市肿瘤医院 | 一种局部晚期胰腺癌适形调强放疗增敏、减痛药物组合物 |
CN104667123B (zh) * | 2015-01-31 | 2019-03-12 | 青岛市肿瘤医院 | 一种用于局部晚期胰腺癌三维适形调强放疗的中药组合物及其应用 |
CN105687823A (zh) * | 2016-01-28 | 2016-06-22 | 陈西成 | 胰腺癌患者化疗后服用的制剂及制法 |
CN105708929A (zh) * | 2016-03-31 | 2016-06-29 | 韩常英 | 胰腺癌患者放化疗期间服用的具有增效作用的制剂及制法 |
CN114887004A (zh) * | 2022-06-02 | 2022-08-12 | 复旦大学附属中山医院 | 一种用于治疗胰腺癌的中药组合物及其应用 |
-
2002
- 2002-08-01 CN CN 02136330 patent/CN1225258C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1391949A (zh) | 2003-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101947284B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN101612357A (zh) | 一种***的中药组合物及其制备方法 | |
CN101711848B (zh) | 一种辅助***的中药组合物 | |
CN101091769B (zh) | 一种治疗和预防食道癌、胃癌的药物及其制备方法 | |
CN102764371B (zh) | 一种减轻放疗副反应的中药复方及其制备方法和应用 | |
CN1225258C (zh) | 一种治疗胰腺癌的中药复方制剂 | |
CN103463554B (zh) | 一种治疗恶性肿瘤的药物组合物及制备方法和用途 | |
CN108186794B (zh) | 一种治疗肺癌的中药组合物及其制备方法和应用 | |
CN102028924B (zh) | 一种用于晚期胃癌的药物组合物 | |
CN101391004B (zh) | 一种用于晚期食管癌的药物组合物 | |
CN103550718B (zh) | 一种治疗肺癌的中药组合物 | |
CN105770263A (zh) | 一种肿瘤辅助治疗的中药制剂及其制备方法 | |
CN101474388B (zh) | 一种改进的仙蟾片药物处方及其制备方法 | |
CN103417911A (zh) | 化疗辅助用中药组合物 | |
CN104127684A (zh) | 一种治疗癌症的中药复方制剂 | |
CN103948859A (zh) | 一种抗肿瘤中药复方制剂及其制备方法和应用 | |
CN1478495A (zh) | 一种抗癌中药药物组合物及其制备方法 | |
CN103768519B (zh) | 一种提高环磷酰胺抗肿瘤疗效的复方药物及其制备方法 | |
CN101007114B (zh) | 一种肿瘤患者辅助用药品或保健品及其制备方法 | |
CN102836315A (zh) | 一种预防调理转归肿瘤的中药组合物及其制备方法 | |
CN101693096A (zh) | 一种治疗肝癌的药物及其制备方法 | |
CN105920436A (zh) | 一种用于治疗肺癌的药物制剂及其制备方法 | |
CN1092972C (zh) | 一种抗肿瘤及抗癌转移的药物 | |
CN1194717C (zh) | 治疗肺癌的蛇毒胶囊及制备方法 | |
CN104689246B (zh) | 一种治疗胃癌的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SAIDE BIOLOGICAL STOCKS CO., LTD., SHANGHAI CITY Free format text: FORMER OWNER: TUMOR HISPITAL ATTACHED TO FUDAN UNIV. Effective date: 20041015 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20041015 Address after: 201203, Zhangjiang Road, Zhangjiang, Pudong, No. 1, Curie Road, Shanghai Applicant after: Shanghai Celstar Bio-pharmaceutical Holding Co., Ltd. Address before: 200032 No. 270, Dongan Road, Shanghai Applicant before: Tumor Hispital Attached to Fudan Univ. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TUMOR HISPITAL ATTACHED TO FUDAN UNIV. Free format text: FORMER OWNER: SAIDE BIOLOGICAL STOCKS CO., LTD., SHANGHAI CITY Effective date: 20080215 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080215 Address after: No. 270, Dongan Road, Shanghai Patentee after: Tumor Hispital Attached to Fudan Univ. Address before: No. 1 Curie Road, Zhangjiang, Shanghai, Pudong Patentee before: Shanghai Celstar Bio-pharmaceutical Holding Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051102 Termination date: 20190801 |
|
CF01 | Termination of patent right due to non-payment of annual fee |